Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Reata Pharma Cla (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,832,388
  • Shares Outstanding, K 29,777
  • Annual Sales, $ 53,590 K
  • Annual Income, $ -80,550 K
  • 60-Month Beta 3.17
  • Price/Sales 52.69
  • Price/Cash Flow N/A
  • Price/Book 185.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.97
  • Number of Estimates 4
  • High Estimate -0.94
  • Low Estimate -1.03
  • Prior Year 0.15
  • Growth Rate Est. (year over year) -746.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.11 +10.46%
on 02/21/19
104.53 -11.12%
on 03/05/19
+6.59 (+7.63%)
since 02/19/19
3-Month
47.50 +95.60%
on 12/21/18
104.53 -11.12%
on 03/05/19
+38.16 (+69.70%)
since 12/19/18
52-Week
19.31 +381.15%
on 03/29/18
104.53 -11.12%
on 03/05/19
+70.16 (+308.40%)
since 03/19/18

Most Recent Stories

More News
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results

PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019

RETA : 92.91 (-2.32%)
Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RETA : 92.91 (-2.32%)
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 92.91 (-2.32%)
Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Geoffrey A. Block, M.D., as Vice President, Nephrology.

RETA : 92.91 (-2.32%)
Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Administration...

RETA : 92.91 (-2.32%)
Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG Mortgage Investment Trust,...

ASB : 22.72 (-3.15%)
NATH : 69.35 (-0.93%)
RETA : 92.91 (-2.32%)
UFCS : 44.74 (-1.41%)
MITT : 17.65 (-0.34%)
ICPT : 111.97 (-1.40%)
Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs

CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020

RETA : 92.91 (-2.32%)
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome

Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36

RETA : 92.91 (-2.32%)
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference

Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models

RETA : 92.91 (-2.32%)
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin), received designation...

RETA : 92.91 (-2.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RETA with:

Business Summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address...

See More

Key Turning Points

2nd Resistance Point 97.98
1st Resistance Point 95.44
Last Price 92.91
1st Support Level 91.57
2nd Support Level 90.24

See More

52-Week High 104.53
Last Price 92.91
Fibonacci 61.8% 71.98
Fibonacci 50% 61.92
Fibonacci 38.2% 51.86
52-Week Low 19.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar